SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 20, 2005
ALKERMES, INC.
(Exact Name of Registrant as Specified in its Charter)
| |
|
|
|
|
PENNSYLVANIA
(State or Other Jurisdiction of
Incorporation)
|
|
1-14131
(Commission
File Number)
|
|
23-2472830
(I.R.S. Employer
Identification No.) |
| |
|
|
88 Sidney Street
Cambridge, Massachusetts
(Address of principal executive offices)
|
|
02139
(Zip Code) |
Registrant’s telephone number, including area code: (617) 494-0171
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 7.01 Regulation FD Disclosure.
On September 20, 2005, Alkermes
announced that the FDA extended the PDUFA date for
Vivitrex® to December 30, 2005. A copy of the press release is furnished as Exhibit
99.1. This information shall not be deemed “filed” for purposes of Section 18 of the Exchange Act,
or incorporated by reference in any filing under the Securities Act or the Exchange Act.